Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo with facial involvement in adults and adolescents, aged 12 years and above. Opzelura is a cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib. It has been approved in the European Union (EU) to offer support for repigmentation […]
Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients, aged 12 and older. Opzelura is a cream formulation of ruxolitinib, which selectively inhibits JAK1/JAK2. Opzelura FDA approval for vitiligo […]
Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical firm, to develop and commercialize three investigational cancer drugs. The agreement, valued at up to $391.5 million, covers pemigatinib, a FGFR1/2/3 inhibitor; itacitinib, a JAK1 inhibitor; and parsaclisib, a PI3Kδ inhibitor, which are currently in clinical stages. […]